Sarcopenia and peptides — what the evidence actually supports for age-related muscle loss

Sarcopenia is the progressive, age-associated loss of skeletal muscle mass, strength, and physical function. The European Working Group on Sarcopenia in Older People 2 (EWGSOP2) recast the diagnostic logic in 2019 around three components: low muscle strength as the primary entry criterion (grip strength ≤27 kg in men, ≤16 kg in women), low muscle quantity or quality as confirmation, and poor physical performance (slow gait speed, chair-rise difficulty) as the severity grade (Cruz-Jentoft et al., Age Ageing 2019, 48(1):16–31). The shift in the EWGSOP2 framework matters mechanistically: muscle mass was demoted from primary diagnostic criterion to confirmatory finding, because mass without strength does not predict the outcomes (falls, fractures, loss of independence, mortality) that make sarcopenia a clinical priority in the first place (Sayer and Cruz-Jentoft, Age Ageing 2022, 51(10):afac220).

The prevalence is large and skews steeply with age. Across community-dwelling cohorts measured against the EWGSOP/AWGS framework, sarcopenia affects roughly 5–13% of adults aged 60–70 and 11–50% of those aged 80 and older, with the wide range driven primarily by which diagnostic algorithm is applied (Mayhew et al., Age Ageing 2019, 48(1):48–56). The condition received its own ICD-10-CM code (M62.84) in 2016, formally separating age-related muscle failure from cachexia, inflammatory myopathy, and disuse atrophy (Anker, Morley and von Haehling, J Cachexia Sarcopenia Muscle 2016, 7(5):512–514).

Sarcopenia is part of the territory where peptide pharmacology meets aging biology. The growth-hormone axis declines with age — somatotroph output drops, IGF-1 falls, the pulse architecture flattens — and that decline is one of several upstream contributors to the loss of muscle mass and quality across the seventh and eighth decades. The GH/IGF-1 axis modulators on this site are mechanistically plausible candidates for sarcopenia management, and the most-cited single peptide trial in the indication (Nass et al. 2008) sits within this corpus. The honest framing across the entire class is the one this dossier walks: mechanism is plausible, mass-effect signals are real, but the strength and functional endpoints that define sarcopenia clinically have been substantially harder to move than the mass endpoints.